GiACTA Part 1 at conclusion, different gps obvious: In remission no treatment In remission on treatment Recently active, on treatment GiACTA Part 2 Aims: Long term safety of TCZ-treated GCA Explore maintenance of efficacy after TCZ discontinuation #ACR19 @rheumnow Abst0808

FINCH3: in this cohort naive to MTX pre-trial, interesting that safety looks good! Maybe too early to tell #ACR19 @rheumnow Abst0927 #ACRbest https://t.co/QCdC8UQR3f

Fenebrutinib- Conclusions from phase2. How does this compare to our other small molecules? Will trial development continue? #ACR19 @rheumnow Abst0929 https://t.co/5ahkmSB11X

Awesome to hang out with my friends @psufka and @DrBhana to record an episode of ACR on Air on location at #ACR19 ! https://t.co/WeolRLGs17

25% of SLE and RA patients at this academic practice were receiving HCQ above recommended doses, by @SkorupaTara & @RobShmerling #ACR19 @rheumnow #Abstr #ACRBest https://t.co/pq379l9ZPH

Holy smokes! 18x higher risk of cardiovascular disease in Black SLE patients, highest at 1 and 10 years after diagnosis - Dr Shivani Garg    #ACR19 @rheumnow #Abstr  #ACRBest https://t.co/kXoMNu4QKb

A second study (after MAINRITSAN) showing the superiority of rituximab vs. azathioprine for maintenance of remission in ANCA-associated vasculitis, by Dr. Rona Smith #ACR19 @rheumnow #Abstr  #ACRBest https://t.co/H8VJiFhp6z

GCA is really a chronic disease, difficult to maintain remission off meds, regardless of initial treatment strategy. Findings from Part 2 of the GIACTA trial of tocilizumab for GCA. Dr. John Stone #ACR19 @rheumnow #Abstr  #ACRBest https://t.co/gxdQrH0pUj

BeSt for Kids study showed comparable efficacy of sequential monotherapy, MTX+pred, or MTX+Etanercept. However, many patients had TNFi added or TNFi switched to achieve inactive disease #ACR19 @rheumnow #Abstr  #ACRBest https://t.co/p5xdJznNhN

Amazing! Most patients with systemic JIA who receive anakinra as first line monotherapy achieved drug-free remission. Dr Ravelli  #ACR19 @rheumnow #Abstr  #ACRBest https://t.co/cWUdUo6dmM

Systemic JIA may be a biphasic disease with early autoinflammatory phenotype and later autoimmune features. Dr. Ravelli  #ACR19 @rheumnow #Abstr  #ACRBest https://t.co/CsZeBOqeRH

Interesting to see worldwide differences is JIA subtypes and ages of onset. Dr Ravelli  #ACR19 @rheumnow #Abstr  #ACRBest https://t.co/MdrPTmixw9

New Eurofever / PRINTO criteria for #autoinflammatory diseases. Dr. Ravelli #ACR19 @rheumnow #Abstr  #ACRBest https://t.co/S35Ltegz1F

Cool view of the immune system as a spectrum from immunodeficiency to autoimmunity. Dr Binstadt #ACR19 @rheumnow #Abstr  #ACRBest https://t.co/b77LA9HbHQ

A wall of donuts. That is the best thing I’ve seen at #ACR19 https://t.co/GS6WntpCFc